Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 April 2007, Vol. 109, No. 8, pp. 3611-3612.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singhal, S.
Right arrow Articles by Mehta, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singhal, S.
Right arrow Articles by Mehta, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents

CORRESPONDENCE

The serum-free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias

To the editor:

The serum-free light chain (SFLC) assay provides useful information in patients with plasma cell dyscrasias who secrete no or small quantities of monoclonal protein.1,2 Changes in SFLC over a period of time correlate with changes in the amounts of 24-hour urinary monoclonal protein.3 It has been suggested that "serum measurements may provide a logical and feasible alternative to 24-hour urine collections" in patients with myeloma.3(p 657) The 2005 myeloma diagnosis and management guidelines from the British Committee for Standards in Haematology4(p 412) state that "[Q]uantification of serum-free immunoglobulin light chain levels (FLC assay) and {kappa}/{lambda} ratio can be used as an alternative to quantifying urinary light chains." These statements are open to the interpretation that 24-hour urine collection can be given up in favor of estimating SFLC in myeloma.

The extent of proteinuria is a powerful predictor of the development of renal dysfunction. There is a correlation between the degree of proteinuria and the rate of progression of renal failure. Thus, proteinuria is an independent mediator of progressive renal dysfunction and not just evidence of glomerular dysfunction.57 Proteinuria in patients with myeloma consists not only of light chains, but also of albumin and other normal proteins that are not estimated by the SFLC assay.

We explored the relationship between proteinuria and SFLC in 174 samples from 135 patients with myeloma. Patients were at varying stages of the disease and therapy, ranging from initial presentation to remission after therapy to relapse.

The serum-free {kappa} and {lambda} light chain levels were 0.59 to 2330 mg/L (median, 18.6 mg/L) and 0.85 to 4950 mg/L (median, 19.8 mg/L), respectively. The ratio was normal (0.26-1.65) in 56% of samples, low in 11% of samples, and high in 33% of samples. Total 24-hour proteinuria was 23 to 7378 mg (median, 166 mg), and monoclonal proteinuria, quantified in 39 (23%) patients, was 24 to 2349 mg (median, 171 mg). Serum creatinine levels were 2.652 to 928.2 µM (0.3-10.5 mg/dL) (median, 97.24 µM [1.1 mg/dL]).

As Table 1 shows, higher amounts of total and monoclonal proteinuria were more likely to be associated with abnormal ratio. However, more than 40% of patients with more than 500 mg urine protein per day had normal ratios, suggesting that reliance upon the ratio as a substitute for 24-hour urine collection would have resulted in missing clinically significant proteinuria in a substantial number of patients. In addition, one-third of patients with small amounts of monoclonal protein in the urine had normal ratios. As Table 2 shows, normal and abnormal ratios were uniformly distributed across different serum creatinine ranges, suggesting lack of correlation between renal function and SFLC. On the other hand, the relationship between serum creatinine and proteinuria was very strong.


View this table:
[in this window]
[in a new window]

 
Table 1. Correlation between serum free light chain ratio and proteinuria

 


View this table:
[in this window]
[in a new window]

 
Table 2. Correlation between serum free light chain ratio, serum creatinine level, and proteinuria

 
The correlation between serum creatinine and proteinuria does not imply that serum creatinine is a substitute for measurement of protein excretion. Rather, it suggests a parallel relationship between increasing proteinuria and progressive renal dysfunction. Detection of proteinuria in myeloma, in addition to suggesting disease activity, should also prompt a search for amyloid deposition, treatment-related toxicity, and modification of therapy (eg, modification of the type of bisphosphonate used or the addition of angiotensin-converting enzyme inhibitor therapy).

Our data show that a normal SFLC ratio cannot rule out significant total proteinuria, that SFLC is not 100% sensitive in detecting monoclonal proteinuria, and the extent of proteinuria but not the SFLC ratio correlates with renal function. The SFLC assay cannot replace 24-hour urine protein estimation from a clinical standpoint. Any recommendation to the contrary runs the risk of suboptimal patient management.

Authorship

Correspondence: Seema Singhal, 676 N St Clair St, Ste 850, Chicago, IL 60611; e-mail: s-singhal{at}northwestern.edu.

Author contributions: S.S. and J.M. treated the patients, designed the study, analyzed and interpreted the data, and wrote the paper. R.S. collected the data and helped with data interpretation. E.V. helped with patient management and data interpretation.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Seema Singhal, Regina Stein, Eric Vickrey, and Jayesh Mehta

References

  1. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97:2900–2902.[Abstract/Free Full Text]

  2. Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. Diagnostic performance of quantitative {kappa} and {lambda} free light chain assays in clinical practice. Clin Chem 2005; 51:878–881.[Abstract/Free Full Text]

  3. Abraham RS, Clark RJ, Bryant SC, et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem 2002; 48:655–657.[Free Full Text]

  4. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006; 132:410–451.[CrossRef][Medline] [Order article via Infotrieve]

  5. Burton C and Harris KP. The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 1996; 27:765–775.[Medline] [Order article via Infotrieve]

  6. Locatelli F, Marcelli D, Comelli M, et al. Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Nephrol Dial Transplant 1996; 11:461–467.[Abstract/Free Full Text]

  7. Tryggvason K and Pettersson E. Causes and consequences of proteinuria: the kidney filtration barrier and progressive renal failure. J Intern Med 2003; 254:216–224.[CrossRef][Medline] [Order article via Infotrieve]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
S. Singhal, E. Vickrey, J. Krishnamurthy, V. Singh, S. Allen, and J. Mehta
The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios
Blood, July 2, 2009; 114(1): 38 - 39.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
M. R. Snyder, R. Clark, S. C. Bryant, and J. A. Katzmann
Quantification of Urinary Light Chains
Clin. Chem., October 1, 2008; 54(10): 1744 - 1746.
[Full Text] [PDF]


Home page
BloodHome page
A. Dispenzieri, L. Zhang, J. A. Katzmann, M. Snyder, E. Blood, R. DeGoey, K. Henderson, R. A. Kyle, M. M. Oken, A. R. Bradwell, et al.
Appraisal of immunoglobulin free light chain as a marker of response
Blood, May 15, 2008; 111(10): 4908 - 4915.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singhal, S.
Right arrow Articles by Mehta, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singhal, S.
Right arrow Articles by Mehta, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020